Abstract
Bile acids are a peculiar class of steroidal compounds that never cease to amaze. From being simple detergents with a primary role in aiding the absorption of fats and fat-soluble vitamins, bile acids are now widely considered as crucial hormones endowed with genomic and non-genomic functions that are mediated by their interaction with several proteins including the nuclear receptor Farnesoid X Receptor (FXR). Taking advantages of the peculiar properties of bile acids in interacting with the FXR receptor, several biliary derivatives have been synthesized and tested as FXR ligands. The availability of these compounds has contributed to characterize the receptor from a structural, patho-physiological and therapeutic standpoint. Among these, obeticholic acid is a first-in-class FXR agonist that is demonstrating hepatoprotective effects upon FXR activation in patients with liver diseases such as primary biliary cirrhosis and nonalcoholic steatohepatitis. This review provides an historical overview of the rationale behind the discovery of obeticholic acid and chemical tools generated to depict the molecular features and bio-pharmacological relevance of the FXR receptor, as well as to summarize structure-activity relationships of bile acid-based FXR ligands so far reported.
Keywords: Bile acids, Farnesoid X receptor, Structure-activity relationships, Structure-property relationships, TGR5.
Current Topics in Medicinal Chemistry
Title:Bile Acid Derivatives as Ligands of the Farnesoid X Receptor: Molecular Determinants for Bile Acid Binding and Receptor Modulation
Volume: 14 Issue: 19
Author(s): Antimo Gioiello, Bruno Cerra, Serena Mostarda, Chiara Guercini, Roberto Pellicciari and Antonio Macchiarulo
Affiliation:
Keywords: Bile acids, Farnesoid X receptor, Structure-activity relationships, Structure-property relationships, TGR5.
Abstract: Bile acids are a peculiar class of steroidal compounds that never cease to amaze. From being simple detergents with a primary role in aiding the absorption of fats and fat-soluble vitamins, bile acids are now widely considered as crucial hormones endowed with genomic and non-genomic functions that are mediated by their interaction with several proteins including the nuclear receptor Farnesoid X Receptor (FXR). Taking advantages of the peculiar properties of bile acids in interacting with the FXR receptor, several biliary derivatives have been synthesized and tested as FXR ligands. The availability of these compounds has contributed to characterize the receptor from a structural, patho-physiological and therapeutic standpoint. Among these, obeticholic acid is a first-in-class FXR agonist that is demonstrating hepatoprotective effects upon FXR activation in patients with liver diseases such as primary biliary cirrhosis and nonalcoholic steatohepatitis. This review provides an historical overview of the rationale behind the discovery of obeticholic acid and chemical tools generated to depict the molecular features and bio-pharmacological relevance of the FXR receptor, as well as to summarize structure-activity relationships of bile acid-based FXR ligands so far reported.
Export Options
About this article
Cite this article as:
Gioiello Antimo, Cerra Bruno, Mostarda Serena, Guercini Chiara, Pellicciari Roberto and Macchiarulo Antonio, Bile Acid Derivatives as Ligands of the Farnesoid X Receptor: Molecular Determinants for Bile Acid Binding and Receptor Modulation, Current Topics in Medicinal Chemistry 2014; 14 (19) . https://dx.doi.org/10.2174/1568026614666141112100208
DOI https://dx.doi.org/10.2174/1568026614666141112100208 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Current Pharmaceutical Design Impact of Sitagliptin on Non-diabetic Covid-19 Patients
Current Molecular Pharmacology Progress in Understanding Basal Ganglia Dysfunction as a Common Target for Methamphetamine Abuse and HIV-1 Neurodegeneration
Current HIV Research The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Polymeric Nanoparticles for Ophthalmic Drug Delivery: An Update on Research and Patenting Activity
Recent Patents on Nanomedicine Mechanisms of HIV-1 Tat Neurotoxicity via CDK5 Translocation and Hyper-Activation: Role in HIV-Associated Neurocognitive Disorders
Current HIV Research Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease
Current Neuropharmacology Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Viral and Cellular Cytokines as Therapeutic Targets in AIDS-Related Lymphoproliferative Disorders
Current Drug Targets - Cardiovascular & Hematological Disorders FXR, A Therapeutic Target for Bile Acid and Lipid Disorders
Mini-Reviews in Medicinal Chemistry microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA Reproductive Effects of Low-to-Moderate Medical Radiation Exposure
Current Medicinal Chemistry Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine